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Summary Statement 
Transient improvement in visual acuity occurs when patients undergoing chronic ranibizumab 
are switched to aflibercept therapy for treatment of neovascular age-related macular 
degeneration. 
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ABSTRACT 
Purpose: To assess whether visual benefits exist in switching to aflibercept in patients who have 
been chronically treated with ranibizumab for neovascular age-related macular degeneration 
(nvAMD).  
Methods: We performed a multicenter, national electronic medical record database study. 
Patients undergoing 6 continuous monthly ranibizumab injections and then switched to 
continuous aflibercept were matched to patients on continuous ranibizumab therapy. Matching 
was performed in a 2:1 ratio and based on visual acuity (VA) 6 months prior to and at the time of 
the switch, and the number of prior ranibizumab injections. 
Results: Patients who were switched to aflibercept demonstrated transiently significant 
improvement in VA that peaked at an increase of 0.9 ETDRS letters three months after the switch 
while control patients continued on ranibizumab treatment showed a steady decline in VA. VA 
differences between the groups were significant (p <0.05) at two, three, and five months after the 
switch. Beginning at four months after the switch, the switch group showed a VA decline similar 
to the control group.  
Conclusion: Transient, non-sustained improvement in VA occurs when switching between anti-
vascular endothelial growth factor (anti-VEGF) agents, which may have implications in treating 
patients on chronic maintenance therapy on one anti-VEGF medication.   
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INTRODUCTION 
Age-related macular degeneration (AMD), the leading cause of blindness in North Americans and 
Europeans of age 50 years and over,1,2 currently affects approximately 6.5% of Americans aged 
40 years and older.3 This blinding eye disease is classified into two types of pathologies. Non-
neovascular AMD is characterized by drusen formation, which damages photoreceptors and 
contributes to the geographic atrophy of the macula. Approximately 85-90% of people with AMD 
have the non-neovascular form. Neovascular AMD (nvAMD) is characterized by choroidal 
neovascularization (CNV) and responsible for 80-90% of AMD cases of blindness.4 
The current treatment method of nvAMD consists of intravitreal inhibitors of vascular endothelial 
growth factor (VEGF), a key player in CNV pathogenesis. The pivotal trials, Anti-VEGF antibody 
for the Treatment of Predominantly Classical Choroidal Neovascularization in AMD (ANCHOR) 
and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of 
Neovascular AMD (MARINA), have shown the efficacy of ranibizumab over photodynamic therapy 
or sham injections.5,6 Comparison of AMD Treatment Trials (CATT) study has demonstrated no 
inferiority between fixed monthly dosing of ranibizumab and bevacizumab in treatment naïve 
patients.7 However, no trial has assessed the effect of cross-over between anti-VEGF agents.  
Today, clinicians encounter more than one anti-VEGF choice in treating patients with nvAMD. 
The contributing factors toward choosing one agent over the rest include cost, frequency of 
dosing, physician’s preference, patients’ insurance status, and other literature findings.8,9 
Tachyphylaxis, the acutely progressive weakening of a pharmacological response due to long-
term or repeated exposure to a drug,10 has been previously described in patients with nvAMD and 
several studies of small sample size have reported conflicting results with some showing possible 
clinical benefits of switching between anti-VEGF agents but others with no significant 
advantage.11,12 (Add all the new references here) However, no large study has determined the 
clinical significance and duration of possible tachyphylaxis in patients undergoing chronic 
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intravitreal anti-VEGF injections for AMD, which has important clinical implications since many 
patients are maintained on chronic monotherapy. 
In the United Kingdom, ranibizumab was used exclusively to treat exudative AMD in the 
National Health Service (NHS) until aflibercept was approved in 2012. A significant portion of 
patients were switched from ranibizumab to aflibercept dosing at this time, providing us with rich 
clinical data with outcomes on the patients who continued ranibizumab vs. those who switched.  
The purpose of this study was to compare the visual outcomes of patients who switched from 
ranibizumab to aflibercept with those who continued ranibizumab therapy. 
 
SUBJECTS & METHODS  
Anonymized data were extracted from the electronic medical record (EMR) system (Medisoft 
Ophthalmology, Medisoft Limited, Leeds, UK) of 20 UK. The Caldicott Guardian (responsible 
nominee for data protection) gave approval for anonymized data extraction. Anonymized 
database analyses of this type do not require full ethical permission as they are viewed as an 
audit or service evaluation (see http://www.hra.nhs.uk/research-community/before-you-
apply/determine-whether-your-study-is-research/). This study was conducted in accordance with 
the declaration of Helsinki, and the UK’s Data Protection Act. Medisoft Limited (Leeds, UK) has a 
structured data set for the management of nvAMD that allows the rapid pooling of the data fields 
collected. This data set was defined and set up before the date of first data collection into this 
study. Data collected at all sites included visual acuity (VA) for each eye (and the method of 
measurement) and treatment if required (with procedure details and complications). 
Data Variables 
Study eyes were identified with the diagnosis of nvAMD undergoing ranibizumab therapy. In this 
report, the ‘best-measured VA’ was the best VA with refraction or habitual correction and/or 
pinhole as measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and 
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expressed as ETDRS letters, which is the mandated way of collecting VA in the UK for anti-VEGF 
treated patients. All analyses were performed using ETDRS letters. Data variables also extracted 
included age, gender, site of treatment, dates of assessment visits, and dates of intravitreal 
therapy. 
Matching 
Figure 1 outlines the treatment sequence of patients in the switched and continuous 
ranibizumab groups. Patient eyes that were treated with at least 1 year of therapy since the 
initiation of therapy for nvAMD, at least 6 monthly, continuous ranibiuzmab therapy, and treated 
with at least 3 aflibercept injections after switching from ranibizumab were identified. These 
patient eyes were then matched to control eyes that were treated with at least 1 year of therapy 
since the initiation of therapy for nvAMD, at least 6 monthly, continuous ranibizumab therapy, 
and treated with at least 3 additional ranibizumab injections. Neither group changed therapies 
after initially switching to aflibercept or remaining on ranibizumab for the remainder of the study. 
The matching ratio was fixed in a 2:1 ratio and the criteria for matching were the number of prior 
ranibizumab injections at the time of the switch within 5 injections, the visual acuity at the time of 
the switch within 5 ETDRS letters, and the visual acuity at 6 months prior to the switch within 5 
ETDRS letters. The matching was performed using a pseudorandom number generator and a 
total of 100,000 random permutations were tested to identify the matching that yielded in the 
highest number of patients matched.  
 
Imputations 
The visual acuities were imputed using last observation carried forward and the relative visual 
acuity difference for each patient eye was calculated with the reference being the visual acuity 
at the time of switching. The mean visual acuities for each month for 6 months prior and 6 
months after switching were evaluated.  
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Statistical Analyses 
A generalized linear model was used to evaluate the difference in relative VA at each month 
after switching between the groups adjusted for age at the time of switching, the number of 
ranibizumab injections at the time of switching, and the visual acuities at 6 months prior and at 
the time of switching. All analyses were performed using Ruby (http://www.ruby-lang.org) and R 
(http://www.r-project.org).  
 
RESULTS 
A total of 1,344 patients treated with intravitreal ranibizumab injections were included in the 
study. A total of 448 patients were switched from ranibizumab to aflibercept and 896 patients 
were matched with continued ranibizumab injections. Table 1 shows the baseline demographic 
characteristics of the patients. 
Six months prior to the switch, the VA of the control and switch groups was 1.3 ETDRS letters 
and 1.7 letters higher than at the time of the switch, respectively (Figure 2). Two months after 
the switch, the switch group demonstrated improvement from 0 to 0.74 letters, while the control 
group resulted in 0.71 letters of VA loss. Six months after the switch, VA for the control and 
switch groups had declined to -1.3 and -0.75 letters, respectively.  On multivariate analysis, the 
relative visual acuity in the switch group was significantly higher (p <0.05) than the control group 
at months 2, 3 and 5 after the switch (Table 1, Figure 3).  
 
DISCUSSION 
Our study demonstrates that when patients are switched from ranibizumab to aflibercept 
injections, a statistically significant but transient improvement in VA occurs at two, three and five 
months after the switch. Following the transient improvement, a decline in VA occurs four to six 
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months after the switch, similar to the control group.  Even at month 2 and 3, the difference in 
letters read were 1.5 and 1.3, which is not deemed to be clinically relevant when compared with 
the non-inferiority limit of 5 letters set in the CATT study.7  
Several hypotheses could explain our study findings. First, aflibercept may be superior to 
ranibizumab in inhibiting VEGF-A, given that aflibercept has a binding affinity that is nearly 140 
times that of ranibizumab.14 In addition, Stewart and Rosenfeld predicted that the intraocular 
biological activity of aflibercept at 10 weeks after a single injection is comparable to ranibizumab 
activity at 30 days, based on a mathematical model that assumes the molecular mass of an 
antibody is proportional to its intravitreal half-life.14 Thus, aflibercept may be more effective for 
longer durations compared to ranibizumab. However, the VEGF Trap-Eye: Investigation of 
Efficacy and Safety in Wet AMD Trials (VIEW 1, VIEW 2) did not demonstrate superiority of 
aflibercept in preventing moderate visual acuity loss over ranibizumab after 1 year of 
treatment.15 
On the other hand, tachyphylaxis may have developed during the long-term use of ranibizumab 
prior to the switch. Tachyphylaxis occurs when cells acutely respond to drug treatment by 
downregulating signaling pathways downstream from their receptors to return to homeostasis.16 
The patients who were switched to aflibercept may have shown improvement in vision due to 
the use of a novel biological agent rather than its superiority. This explanation is substantiated 
by the transient, rather than long-term nature of VA improvement observed in patients who 
switched to aflibercept, as shown in a retrospective case series conducted by Slean et al17 In 
this study, a total of 80 nvAMD eyes were initially treated with an average of 20.71 injections of 
bevacizumab and/or ranibizumab and then switched to aflibercept. The median central macular 
thickness (CMT) improved transiently from 317 μm to 285 μm after the switch. However, CMT 
later worsened to a median of 296 μm after continuous aflibercept treatments. Interestingly, 
after a total average of 7.2 aflibercept injections, 21 eyes (19 patients) were switched back to 
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either ranibizumab or bevacizumab due to recurrent fluid or VA decline. After the switch, the 
eyes demonstrated transient improvement in CMT (283 μm) again. Even though fluid followed a 
similar trend throughout the transitions, median VA showed little apparent change. Slean et al 
concluded that nvAMD eyes with recurrent fluid may demonstrate a therapeutic response to 
periodically rotating anti-VEGF agents.17 
Prior smaller studies have similarly investigated whether tachyphylaxis occurs during anti-VEGF 
treatments. In a review of the literatures on the treatment of refractive nvAMD to bevacizumab 
and/or ranibizumab,1 five small studies of 26 to 65 patients showed statistically significant visual 
acuity improvement (p-value <0.05) ranging from 0.5 to 6.9 ETDRS letters and 0.09 to 0.1 
logMAR at 6 months after the switch to aflibercept.2,3,4-6 Additional studies reported visual acuity 
improvement ranging from 0.01 to 0.29 logMAR and 0.2 to 2.5 ETDRS letters but none of these 
changes were statistically significant. 7, 8, 9-12 Thus, the majority of the studies have shown 
either non clinically and/or statistically significant difference in visual benefit at 6 months after 
switching to aflibercept, comparable to our study results.  
Forooghian et al conducted a retrospective review focusing on OCT outcome measures of 59 
patients with nvAMD and reported tachyphylaxis in 6 eyes (5 patients) after 31 to 128 weeks of 
bevacizumab treatment.13 Tachyphylaxis was defined as a loss of therapeutic response 3 to 5 
weeks after bevacizumab administration in an eye that had previously demonstrated a 
therapeutic response in the same time interval within the treatment period. Patients were treated 
with intravitreal bevacizumab as needed based on the intra- or subretinal fluid on spectral 
domain optical coherence tomography (OCT) and followed every 4 weeks for 14 months. In 
another study, Gasperini et al18 identified 10 eyes that were initially treated with bevacizumab 
and then switched to ranibizumab, and 16 eyes that were initially treated with ranibizumab and 
switched to bevacizumab, with a mean follow-up period of 13 months (range 6-28). A total of 21 
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out of 26 eyes with nvAMD demonstrated a transient improvement in therapeutic responses 
after switching treatments, which was similar to the results of our study.  
Our study differs from previous studies due to a substantially larger sample size in a real-world 
clinical setting. The largest of prior studies included 109 patients,13 much smaller than our 
cohort. No other study has performed significant matching on patient eyes based on VA at six 
months prior to the switch and at the time of switch, as well as the number of ranibizumab 
injections at the time of switch, which provides significantly more detailed comparison between 
two groups. In addition, while past studies only included the patients who were treatment 
refractory to bevacizumab and/or ranibizumab, our study patients were switched to aflibercept 
as en-bloc, which addresses the question of how patients respond to aflibercept on chronic 
ranibizumab therapy regardless of their response.  
There are several limitations to our study. We are unable to assess superiority between the two 
anti-VEGF drugs due to the lack of data from patients who switched from aflibercept to 
ranibizumab. Given that aflibercept was FDA-approved only five years ago, we have not 
enrolled a significant number of patients who were initiated on aflibercept and then switched to 
ranibizumab treatment. This lack of data prevents us from determining whether this 
improvement is truly due to tachyphylaxis, although the transient nature of the improvement 
followed by a decline in vision for patients in both groups is suggestive of tachyphylaxis. 
Alternatively, the transient improvement may be due to the increase in frequency of injections 
that occur at the time of the switching. The cohort effect may have biased on the results of our 
study; an inherent difference between patients who were treated with ranibizumab in the early 
2000’s may exist compared to patients who were treated in more recent years.  
Despite these limitations, our study demonstrates that switching patients from ranibizumab to 
aflibercept injections had a clinically not significant yet statistically significant transient 
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improvement in vision. Intravitreal anti-VEGFs will continue to be the primary treatment for 
nvAMD for North Americans and Europeans. Future research on nvAMD should continue to 
explore anti-VEGF drug efficacy and the possible consequence of tachyphylaxis in order to 
optimize the treatment for this presently incurable disease. 
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TABLES 
 
Table 1.  Baseline Characteristics of Two Treatment Groups.  
 Continuous 
ranibizumab 
(n = 896) 
Ranibizumab to 
aflibercept 
(n = 448) 
p-value 
Right eyes, n (%) 453 (50.6) 235 (52.5) 0.525 
Age, mean (SD) 79.3 (7.5) 78.8 (7.7) 0.259 
Visual acuity 6 
months prior to 
switch, mean (SD) 
61.5 (14.7) 61.7 (14.9) 0.815 
Visual acuity at the 
time of switch, 
mean (SD) 
60.1 (14.0) 59.9 (14.3) 0.827 
Number of 
ranibizumab 
injections at the 
time of switching, 
mean (SD) 
20.0 (7.1) 21.0 (7.7) 0.020 
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SD, standard deviation. 
 
 
 
Table 2.  Multivariate Regression Analysis on Change in Visual Acuity.  
Month Change in visual acuity 
 Beta 95% CI p-value 
1 0.566 -0.125, 1.258 0.187 
2 1.376 0.636, 2.116 <0.001 
3 1.227 0.464, 1.991 0.002 
4 0.147 -0.684, 0.978 0.729 
5 0.885 0.033, 1.738 0.042 
6 0.441 -0.507, 1.389 0.362 
CI, confidence interval. 
 
 
 
 
FIGURE LEGENDS 
Fig. 1. Patient treatment sequence. The flow chart illustrates the treatment sequence for 
patients in the switched and continuous ranibizumab groups. Both had a minimum of 1 year of 
intravitreal therapy, a minimum of 6 months of ranibizumab therapy, a minimum of 3 subsequent 
injections following the point of switch, and continued the post-switch therapy for the duration of 
the study period. nvAMD, Neovascular Age-related Macular degeneration.  
 
Fig. 2. Change in visual acuity. The graph illustrates a comparison of visual acuity (relative 
Early Treatment Diabetic Retinopathy Study (ETDRS) letters) over time (months) between the 
switch group and the continuous ranibizumab group. Negative months indicate time before the 
switch. Error bars (± SD). 
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Fig. 3. Visual acuity differences. The graph illustrates the statistical significance of visual acuity 
differences between the switch group and the continuous ranibizumab group by month following 
the switch. The dotted line indicates significance at p = 0.05. 
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